Laobaixing Pharmacy
LBX Pharmacy Chain Joint Stock Company operates a chain of pharmacy stores in Mainland China. The company operates through three segments: Retail business, Wholesale business, and Other. It engages in commodity retail and wholesale business; and pharmaceutical manufacturing business and others, as well as sells drugs, and other health and beauty-related products through its marketing network. The… Read more
Laobaixing Pharmacy (603883) - Total Liabilities
Latest total liabilities as of September 2025: CN¥13.13 Billion CNY
Based on the latest financial reports, Laobaixing Pharmacy (603883) has total liabilities worth CN¥13.13 Billion CNY as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Laobaixing Pharmacy - Total Liabilities Trend (2011–2024)
This chart illustrates how Laobaixing Pharmacy's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Laobaixing Pharmacy Competitors by Total Liabilities
The table below lists competitors of Laobaixing Pharmacy ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Nick Scali Ltd
AU:NCK
|
Australia | AU$442.35 Million |
|
Honeywell Automation India Limited
NSE:HONAUT
|
India | ₹15.52 Billion |
|
Beijing Hualian Hypermarket Co Ltd
SHG:600361
|
China | CN¥16.93 Billion |
|
Cellcom Israel Ltd
PINK:CELJF
|
USA | $3.50 Billion |
|
Blacksky Technology Inc
NYSE:BKSY
|
USA | $289.80 Million |
|
Changzhou Qianhong Biopharma Co Ltd
SHE:002550
|
China | CN¥255.86 Million |
|
TSEC Corp
TW:6443
|
Taiwan | NT$3.30 Billion |
|
Sunway Construction Group Bhd
KLSE:5263
|
Malaysia | RM4.08 Billion |
Liability Composition Analysis (2011–2024)
This chart breaks down Laobaixing Pharmacy's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.87 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.93 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.65 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Laobaixing Pharmacy's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Laobaixing Pharmacy (2011–2024)
The table below shows the annual total liabilities of Laobaixing Pharmacy from 2011 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥14.99 Billion | +7.51% |
| 2023-12-31 | CN¥13.94 Billion | -2.50% |
| 2022-12-31 | CN¥14.30 Billion | +17.41% |
| 2021-12-31 | CN¥12.18 Billion | +87.99% |
| 2020-12-31 | CN¥6.48 Billion | +7.09% |
| 2019-12-31 | CN¥6.05 Billion | +18.26% |
| 2018-12-31 | CN¥5.12 Billion | +42.18% |
| 2017-12-31 | CN¥3.60 Billion | +21.37% |
| 2016-12-31 | CN¥2.96 Billion | +96.50% |
| 2015-12-31 | CN¥1.51 Billion | +4.47% |
| 2014-12-31 | CN¥1.44 Billion | +14.31% |
| 2013-12-31 | CN¥1.26 Billion | +43.11% |
| 2012-12-31 | CN¥882.72 Million | -3.30% |
| 2011-12-31 | CN¥912.83 Million | -- |